This is a non-core endpoint: only basic statistics are computed.
Endpoint definition
↥
FinnGen phenotype data
429209 individuals
Apply sex-specific rule None
429209
Check conditions None
429209
Check pre-conditions, main-only, mode, registry filters
Medicine purchases: ATC
N06DA03
1 out of 7 registries used, show all original rules.
4084
Check minimum number of events
Min. number of events
3
4084
Include endpoints None
4084
Remove individuals based on genotype QC
3965
ADMED_ACHEI_RIVASTIGMINE
Control definitions
Controls for this endpoint are individuals that are not cases.
Extra metadata
First used in FinnGen datafreeze
DF2
Not enough data for upset plot.
Or the full data table
Similar endpoints
↥List of similar endpoints to
Use of rivastigmine
based on the number of shared cases.
Broader endpoints:
- Use of anticholinesterases
- N06DA Anticholinesterases
- Alzheimer’s disease, wide definition (more control exclusions)
- Alzheimer’s disease, wide definition
- Dementia
Narrower endpoints:
None
Summary Statistics
↥Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 3965 | 1848 | 2117 |
| Unadjusted prevalence (%) | 0.96 | 0.80 | 1.16 |
| Mean age at first event (years) | 78.03 | 78.47 | 77.64 |
Mortality
Not a core endpoint, no data to show.
Age distribution of first events
Year distribution of first events
Cumulative Incidence
Not a core endpoint, no data to show.
Correlations
↥
Index endpoint: ADMED_ACHEI_RIVASTIGMINE – Use of rivastigmine
GWS hits:
Survival analyses between endpoints
↥Not a core endpoint, no data to show.
Drugs most likely to be purchased after Use of rivastigmine
↥Endpoint not on priority list, no data to show.